Multiomic Health Ltd. and Alloy Therapeutics Inc. have signed a memorandum of understanding to jointly discover and develop first-in-class renal tissue-targeting drugs. Precision medicines for chronic renal conditions targeted to the kidney tissue of specific patient subpopulations are expected to improve efficacy and safety compared to conventional systemic drugs.
Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration agreement with Reborna Biosciences Inc. to generate RNA-targeting novel small molecules in the field of the central nervous system.
Navigo Proteins GmbH has established a strategic research collaboration with SCK CEN, the Belgian Nuclear Research Centre, to advance the preclinical development of next-generation radiotheranostics using the Auger-electron emitting radioisotope Terbium (161Tb).
Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration agreement with Reborna Biosciences Inc. to generate RNA-targeting novel small molecules in the field of the central nervous system.
Marengo Therapeutics Inc. has entered into a multiyear research collaboration in oncology and autoimmune diseases with University of Pennsylvania Perelman School of Medicine. The research collaboration will provide deeper insights into the mechanism of action of Marengo’s selective dual T-cell agonists in oncology.
CEPI is partnering with Astrazeneca plc to advance VHH-based multispecific antibodies targeting influenza, while Harbour Biomed Ltd. has entered into a global strategic collaboration with Astrazeneca to discover and develop next-generation multispecific antibodies for immunology, oncology and other diseases.
Quiver Bioscience Inc. is collaborating with the Dup15q Alliance to advance an antisense oligonucleotide (ASO) therapeutic program for chromosome 15q duplication (Dup15q) syndrome.
Opko Health Inc. and Entera Bio Ltd. have entered into a collaboration and license agreement to advance an oral dual agonist GLP-1/glucagon peptide as a once-daily tablet into the clinic for patients with obesity, metabolic and fibrotic disorders.
Pierre Fabre SA and Redridge Bio AG have signed an exclusive R&D collaboration and license agreement to identify and develop biparatopic antibody drug candidates against multiple targets, with a focus on precision oncology, dermatology and rare diseases. The agreement provides for participation by Pierre Fabre in Redridge’s series A financing, as well as up-front, milestone and future sales royalty payments.
Aprea Therapeutics Inc. has entered into a material transfer agreement with MD Anderson Cancer Center that will support investigation of APR-1051 as a potential treatment for head and neck squamous cell carcinoma (HNSCC).
RSS
